M

Madeleine F. Jennewein

Advanced Energy (United States)

ORCID: 0000-0001-6633-7413

Publishes on SARS-CoV-2 and COVID-19 Research, Monoclonal and Polyclonal Antibodies Research, Animal Virus Infections Studies. 45 papers and 3.2k citations.

45Publications
3.2kTotal Citations

Is this you? Claim your profile.

Add your photo, update your bio, and get notified when your ranking changes.

Top publicationsby citations

mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection
Cited by 620Open Access

Boosterism could save lives Postinfection immune protection against severe acute respiratory syndrome coronavirus 2 reinfection is not fully understood. It will be devastating if waves of new variants emerge that undermine natural immune protection. Stamatatos et al. investigated immune responsiveness 4 to 8 months after previously infected individuals were given a messenger RNA–based vaccine developed for the original Wuhan variant (see the Perspective by Crotty). Before vaccination, postinfection serum antibody neutralization responses to virus variants were variable and weak. Vaccination elevated postinfection serum-neutralizing capacity approximately 1000-fold against Wuhan-Hu-1 and other strains, and serum neutralization against the variant B.1.351 was enhanced. Although responses were relatively muted against the variant, they still showed characteristic memory responses. Vaccination with the Wuhan-Hu-1 variant may thus offer a valuable boost to protective responses against subsequent infection with variant viruses. Science , abg9175, this issue p. 1413 ; see also abj2258, p. 1392